BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27123491)

  • 21. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
    Tran TH; Harris MH; Nguyen JV; Blonquist TM; Stevenson KE; Stonerock E; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Reshmi SC; Neuberg DS; Sallan SE; Loh ML; Silverman LB
    Blood Adv; 2018 Mar; 2(5):529-533. PubMed ID: 29507076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.
    Mullighan CG
    Clin Cancer Res; 2011 Feb; 17(3):396-400. PubMed ID: 21149616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss-of-function but not dominant-negative intragenic
    Kobitzsch B; Gökbuget N; Schwartz S; Reinhardt R; Brüggemann M; Viardot A; Wäsch R; Starck M; Thiel E; Hoelzer D; Burmeister T
    Haematologica; 2017 Oct; 102(10):1739-1747. PubMed ID: 28751559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of leukemias with ETV6-ABL1 fusion.
    Zaliova M; Moorman AV; Cazzaniga G; Stanulla M; Harvey RC; Roberts KG; Heatley SL; Loh ML; Konopleva M; Chen IM; Zimmermannova O; Schwab C; Smith O; Mozziconacci MJ; Chabannon C; Kim M; Frederik Falkenburg JH; Norton A; Marshall K; Haas OA; Starkova J; Stuchly J; Hunger SP; White D; Mullighan CG; Willman CL; Stary J; Trka J; Zuna J
    Haematologica; 2016 Sep; 101(9):1082-93. PubMed ID: 27229714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
    Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
    Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IKZF1 Gene Deletion in Pediatric Patients Diagnosed with Acute Lymphoblastic Leukemia in Mexico.
    Ayón-Pérez MF; Pimentel-Gutiérrez HJ; Durán-Avelar MJ; Vibanco-Pérez N; Pérez-Peraza VM; Pérez-González ÓA; Barrientos-Ríos R; Santillán-Ávila CF; Zambrano-Zaragoza JF; Agraz-Cibrián JM; Gutiérrez-Franco J; Vázquez-Reyes A
    Cytogenet Genome Res; 2019; 158(1):10-16. PubMed ID: 30974435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotypic and Functional Alterations of Hematopoietic Stem and Progenitor Cells in an In Vitro Leukemia-Induced Microenvironment.
    Vernot JP; Bonilla X; Rodriguez-Pardo V; Vanegas NP
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Focal adhesion kinase is required for CXCL12-induced chemotactic and pro-adhesive responses in hematopoietic precursor cells.
    Glodek AM; Le Y; Dykxhoorn DM; Park SY; Mostoslavsky G; Mulligan R; Lieberman J; Beggs HE; Honczarenko M; Silberstein LE
    Leukemia; 2007 Aug; 21(8):1723-32. PubMed ID: 17568820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
    Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
    J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
    Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
    Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells.
    Feldhahn N; Henke N; Melchior K; Duy C; Soh BN; Klein F; von Levetzow G; Giebel B; Li A; Hofmann WK; Jumaa H; Müschen M
    J Exp Med; 2007 May; 204(5):1157-66. PubMed ID: 17485517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CXC chemokine ligand 12-induced focal adhesion kinase activation and segregation into membrane domains is modulated by regulator of G protein signaling 1 in pro-B cells.
    Le Y; Honczarenko M; Glodek AM; Ho DK; Silberstein LE
    J Immunol; 2005 Mar; 174(5):2582-90. PubMed ID: 15728464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Why and how to treat Ph-like ALL?
    Roberts KG
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The molecular genetic makeup of acute lymphoblastic leukemia.
    Mullighan CG
    Hematology Am Soc Hematol Educ Program; 2012; 2012():389-96. PubMed ID: 23233609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells.
    Klein F; Feldhahn N; Harder L; Wang H; Wartenberg M; Hofmann WK; Wernet P; Siebert R; Müschen M
    J Exp Med; 2004 Mar; 199(5):673-85. PubMed ID: 14993251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL.
    Roberts KG; Yang YL; Payne-Turner D; Lin W; Files JK; Dickerson K; Gu Z; Taunton J; Janke LJ; Chen T; Loh ML; Hunger SP; Mullighan CG
    Blood Adv; 2017 Sep; 1(20):1657-1671. PubMed ID: 29296813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous detection of ABL1 mutation and IKZF1 deletion in Philadelphia chromosome-positive acute lymphoblastic leukemia using a customized target enrichment system panel.
    Aoe M; Ishida H; Matsubara T; Karakawa S; Kawaguchi H; Fujiwara K; Kanamitsu K; Washio K; Okada K; Shibakura M; Shimada A
    Int J Lab Hematol; 2018 Aug; 40(4):427-436. PubMed ID: 29575541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
    De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
    BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abnormal hematopoiesis and autoimmunity in human subjects with germline IKZF1 mutations.
    Hoshino A; Okada S; Yoshida K; Nishida N; Okuno Y; Ueno H; Yamashita M; Okano T; Tsumura M; Nishimura S; Sakata S; Kobayashi M; Nakamura H; Kamizono J; Mitsui-Sekinaka K; Ichimura T; Ohga S; Nakazawa Y; Takagi M; Imai K; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S; Kojima S; Nonoyama S; Morio T; Kanegane H
    J Allergy Clin Immunol; 2017 Jul; 140(1):223-231. PubMed ID: 27939403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
    Lu XT
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.